The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
Open accessAbstract
Background: The increased prevalence of diabetes in schizophrenia is partly attributed to antipsychotic treatment, in particular second-generation antipsychotics, but the evidence has not been systematically reviewed. Aims: Systematic review and meta-analysis comparing diabetes risk for different antipsychotics in people with schizophrenia. Method: We searched MEDLINE, PsycINFO, EMBASE, International Pharmaceutical Abstracts, CINAHL and Web of Knowledge until September 2006. Studies were eligible for inclusion if the design was cross-sectional, case-control, cohort or a controlled trial in individuals with schizophrenia or related psychotic disorders, where second-generation antipsychotics (defined as clozapine, olanzapine, risperidone and quetiapine) were compared with first-generation antipsychotics and diabetes was an outcome. Data were pooled using random effects inverse variance weighted meta-analysis. Results: Of the studies that met the inclusion criteria (n=14), 11 had sufficient data to include in the meta-analysis. Four of these were retrospective cohort studies. The relative risk of diabetes in patients with schizophrenia prescribed one of the second-generation v. first-generation antipsychotics was 1.32 (95% CI 1.15-1.51). There were insufficient data to include aripiprazole, ziprasidone and amisulpride in this analysis. Conclusions: There is tentative evidence that the second-generation antipsychotics included in this study are associated with a small increased risk for diabetes compared with firstgeneration antipsychotics in people with schizophrenia. Methodological limitations were found in most studies, leading to heterogeneity and difficulty interpreting data. Regardless of type of antipsychotic, screening for diabetes in all people with schizophrenia should be routine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Amos, A. F., McCarty, D. J., & Zimmet, P. (1997) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199712)14:5+<s7::aid-dia522>3.0.co;2-r · Cited by 1,882
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
The Structured Clinical Interview for DSM-III-R (SCID): II. Multisite Test-Retest Reliability
Williams, J. B. W. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080038006 · Cited by 1,618
Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030
Wild, S. H., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2569-a · Cited by 1,477
Moher, D., Jadad, A. R., Nichol, G., Penman, M., Tugwell, P., & Walsh, S. (1995) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)00031-w · Cited by 1,308
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
Epidemiology: Study Design and Data Analysis
(2006) · Technometrics · doi:10.1198/tech.2006.s407 · Cited by 788
Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia
Sernyak, M. J., Leslie, D. L., Alarcon, R. D., Losonczy, M. F., & Rosenheck, R. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.4.561 · Cited by 623
Prevalence and Correlates of Diabetes in National Schizophrenia Samples
Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., & Lehman, A. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033504 · Cited by 569
Lindenmayer, J.-P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.290 · Cited by 465
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421
Diabetes mellitus in schizophrenic patients
Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., & Scapicchio, P. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90054-1 · Cited by 368
Regenold, W. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00456-6 · Cited by 293
Epidemiology: Study Design and Data Analysis
Davies, S. (2006) · Journal of the American Statistical Association · doi:10.1198/jasa.2006.s92 · Cited by 288
Meyer, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0509 · Cited by 267
Jin, H., Meyer, J. M., & Jeste, D. V. (2002) · Annals of Clinical Psychiatry · doi:10.1023/a:1015228112495 · Cited by 249
Gianfrancesco, F. D., Grogg, A. L., Mahmoud, R. A., Wang, R.-H., & Nasrallah, H. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1010 · Cited by 237
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Leslie, D. L., & Rosenheck, R. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1709 · Cited by 212
Hagg, S., Joelsson, L., Mjorndal, T., Spigset, O., Oja, G., & Dahlqvist, R. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0604 · Cited by 211
Lund, B. C., Perry, P. J., Brooks, J. M., & Arndt, S. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.12.1172 · Cited by 194
Epidemiology: Study Design and Data Analysis (2nd ed.)
Davies, S. (2006) · Quarterly Publications of the American Statistical Association · Cited by 172
Atypical Antipsychotic???Induced Diabetes Mellitus: How Strong is the Evidence?
Henderson, D. C. (2002) · CNS Drugs · doi:10.2165/00023210-200216020-00001 · Cited by 162
Schizophrenia, the metabolic syndrome and diabetes
Holt, R. I. G., Peveler, R., & Byrne, C. D. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01199.x · Cited by 155
Self-citationMackin, P., Watkinson, H., & Young, A. H. (2005) · Diabetologia · doi:10.1007/s00125-004-1641-y · Cited by 138
The Risk of Diabetes During Olanzapine Use Compared With Risperidone Use
Jaime, J., Ward, A., Levinton, C. M., & Robinson, K. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1208 · Cited by 131
Antipsychotic-Induced Type 2 Diabetes: Evidence From a Large Health Plan Database
Gianfrancesco, F. D., White, R., Wang, R., & Nasrallah, H. A. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085404.08426.3a · Cited by 123
Lambert, B. L., Cunningham, F. E., Miller, D. R., Dalack, G. W., & Hur, K. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj289 · Cited by 120
Diabetes Mellitus and Impaired Glucose Tolerance in Patients with Schizophrenia
Subramaniam, M., Chong, S., & Pek, E. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800512 · Cited by 115
Citrome, L., Jaffe, A. B., Levine, J., Allingham, B., & Robinson, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.9.1006 · Cited by 111
Melkersson, K. I., & Dahl, M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1529-4 · Cited by 104
Side Effects of Atypical Antipsychotic Drugs
Ananth, J., Parameswaran, S., & Gunatilake, S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384088 · Cited by 91
Lambert, B. L., Chou, C., Chang, K., Tafesse, E., & Carson, W. H. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1092 · Cited by 76
Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria
Holt, R. I. G., & Peveler, R. (2006) · Diabetologia · doi:10.1007/s00125-006-0279-3 · Cited by 64
Self-citationAtypical Antipsychotic Drug Use and Diabetes
Ananth, J., Venkatesh, R., Burgoyne, K. S., & Gunatilake, S. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000064807 · Cited by 59
Cohen, D., Dekker, J., Peen, J., & Wied, C. C. G. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.003 · Cited by 56
Exploring the Association Between Atypical Neuroleptic Agents and Diabetes Mellitus in Older Adults
Etminan, M., Streiner, D. L., & Rochon, P. A. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.14.1411.31939 · Cited by 55
Ollendorf, D. A., Joyce, A. T., & Rucker, M. (2004) · PubMed · Cited by 47
Hyperglycemia and Hypertriglyceridemia in Real World Patients on Antipsychotic Therapy
Gupta, S., Steinmeyer, C. H., Frank, B. L., Madhusoodanan, S., Lockwood, K., Lentz, B., & Keller, P. (2003) · American Journal of Therapeutics · doi:10.1097/00045391-200309000-00007 · Cited by 39
Sacchetti, E., Turrina, C., Parrinello, G., Brignoli, O., Stefanini, G., & Mazzaglia, G. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200501000-00007 · Cited by 36
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine
Brown, R. R., & Estoup, M. W. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00008 · Cited by 31
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Self-citationCorrell, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Metadata
- Authors
- Smith, M., Hopkins, D., Peveler, R. C., Holt, R. I. G., Woodward, M., & Ismail, K.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2008-06
- Volume
- 192
- Issue
- 6
- Pages
- 406-411
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2126642792
- Cited by
- 275
- References
- 47
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.